Tamsulosin Hydrochloride Capsule
Product Images NDC 68071-4443

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 68071-4443). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 4443 9

NuCare Pharmaceuticals, Inc. presents Tamsulosin HCI 0.4mg capsules in a lot of 90 units, presented in an olive green opaque/orange oblong capsule imprinted with "D", "Exp. Date", and "Lot#: 000000". Each capsule contains TansosinHC USP 0.4mg with GTIN 0036807144391 and a Serial# 00000000002. The Manufacturer NDC is 65862-598-05, and the product is RX only, with a warning to keep out of reach of children and stored at a controlled temperature of 68-77°F. Contact the doctor for medical advice about side effects or report them to the FDA at 1-800-FDA-1088.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

The image shows a graph representing the mean change from baseline in Total AUA Symptom Score in a study with two treatment options: an 0.08mg dose of a certain substance and a placebo. The x-axis indicates the duration of the treatment in weeks and the y-axis shows the mean change score from 0 to 35. There are multiple data points for each treatment option, ranging from week 0 to week 13, and the last data point shows the LOCF (last observation carried forward) value.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

This is a figure displaying the mean change from baseline in the Total American Urological Association (AUA) Symptom Score on a scale of 0 to 35, in Study 2. The graph shows the value for different treatments including O=0O—0-08mg LNt 0.4mg, 3 Placebo with the duration of treatment in weeks being displayed on the X-axis. It also shows the number of participants for each treatment option.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

The image shows a graph titled "Mean Increase in Peak Urine Flow Rate (in L/Sec) Study 1". The graph displays the peak urine flow rate in mL/sec for different treatments, including two different dosages (0.08mg and 0.4mg) and a placebo group. The mean change in urine flow rate is shown on the y-axis, and the duration of treatment in weeks is shown on the x-axis. The graph includes four data points for each treatment group, with sample sizes ranging from 617 to 755.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

FDA Label Image

Chemical Structure (Tamsulosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.